NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and year ended December 31, 2025 will be releas…
Uncategorized
Implantations of FineVision HP trifocal IOL begin in US
Surgeons completed the first successful implantations of the FineVision HP trifocal IOL in the U.S., according to a press release from BVI.BVI chief commercial officer Andy Chang told Healio that the FineVision HP IOL was designed to support a high-con…
Uncategorized
VIDEO: Potential ‘management-changing’ results in retina research expected in 2026
WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Allen C. Ho, MD, director of retina research at Wills Eye Hospital, said 2026 is going to be a “really big year” in retina.According to Ho, topline results are expected for tyrosine kinase…
Uncategorized
iVeena Delivery Systems Announces First Patient Dosed in Phase 1 Study of IVMED-85 in Healthy Adult Volunteers
SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company developing novel pharmacologic therapies for refractive eye diseases, today announced that the first participant has been dosed in its Pha…
Uncategorized
Stanton Optical Celebrates Grand Opening of Four Store-in-Store Locations Inside Staples Stores
FRAMINGHAM, Mass. & DELRAY BEACH, Fla.–(BUSINESS WIRE)–Now Optics, parent company of Stanton Optical, and Staples today announced the grand opening of the first four “store-in-store” Stanton Optical locations inside select Staples stores in the Phila…
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that the first patient has been dosed in t…